Senos (aumentar tamaño)

2'-Fucosyllactose (2'-FL) is the most abundant human milk oligosaccharide and functions as a prebiotic that specifically promotes Bifidobacterium growth and gut-brain axis development in infants. Research shows 2'-FL modulates gut microbiota composition, promotes SCFA production, and influences brain development and behavioral outcomes through gut-brain axis mechanisms.

5-HTP is the direct precursor to serotonin, approximately 95% of which is produced in the gut, placing it at the heart of the gut-brain axis. Research in preclinical models shows oral 5-HTP significantly restores gut microbiota dysbiosis associated with depression-like behaviors. It also increases serotonin levels in both the gastrointestinal tract and the brain, directly linking gut serotonin signaling to central mood regulation.

Akkermansia muciniphila is a next-generation probiotic bacterium residing in the gut mucus layer, increasingly recognized for modulating the gut-brain axis. Preclinical studies demonstrate it reduces neuroinflammation, improves cognitive function, and ameliorates depression-like behaviors in stressed animals. Its mechanisms include regulation of serotonin levels, BDNF expression, and intestinal/blood-brain barrier integrity.

Alpha-linolenic acid (ALA) is a plant-derived omega-3 fatty acid that serves as a precursor to EPA and DHA and contributes to gut-brain axis function through conversion to longer-chain omega-3s and direct anti-inflammatory effects on gut microbiota. It modifies gut microbial community composition and influences neuroinflammatory markers relevant to mood and cognition.

B. coagulans operates through the gut-brain axis, modulating gut microbiota to influence neurotransmitter levels (serotonin, GABA, dopamine), inflammatory cytokines, and short-chain fatty acids, with documented effects on depression, anxiety, and stress in clinical trials. Multiple RCTs have measured gut-brain axis biomarkers alongside psychological outcomes.

The published clinical trial on Benegut explicitly frames the gut-brain axis as a central mechanistic rationale, noting that psychosocial stress alters gut physiology via ileum contractions, producing GI symptoms. Clinical improvement in psychosocial quality-of-life outcomes associated with GI discomfort was documented in the Benegut trial. Perilla frutescens compounds including rosmarinic acid also show antidepressant-related activity in preclinical work.

Berberine reshapes gut microbiota composition, modulates enteroendocrine signaling (GLP-1, dopamine precursors), and reduces intestinal barrier permeability, with downstream effects on neuroinflammation and brain function. Clinical and preclinical data document BBR's dual action on both gut homeostasis and neural signaling via the microbiome-gut-brain axis.

Bifidobacterium species are among the most extensively studied probiotics for the gut-brain axis. Multiple strains, particularly B. longum, have shown in human RCTs the ability to reduce stress, improve memory, and modulate brain activity patterns. They produce GABA and increase tryptophan availability, linking gut microbiota to central neurotransmitter regulation.

Bifidobacterium adolescentis is a GABA-producing gut bacterium with demonstrated relevance to the gut-brain axis. It contributes to GABAergic signaling in the gut that can influence brain function and has been shown to affect mental health markers through gut microbiota modulation. It is one of several Bifidobacterium species identified as capable of direct neurotransmitter production.

Bifidobacterium animalis, particularly subspecies lactis, has been studied in gut-brain axis research including a landmark fMRI study showing reduced emotional brain activation following fermented milk consumption. It contributes to gut barrier integrity, SCFA production, and modulation of the HPA stress axis.

Bifidobacterium bifidum has been studied in probiotic formulations targeting gut-brain axis function, including studies in Alzheimer's disease patients where combinations including B. bifidum improved cognitive performance and metabolic profiles. It supports gut barrier integrity and anti-inflammatory signaling relevant to neuropsychiatric health.

Bifidobacterium breve has strong clinical evidence for gut-brain axis effects, notably in cognitive health. B. breve MCC1274 at 2×10¹⁰ CFU/day for 24 weeks reduced cognitive decline and halted brain atrophy in elderly MCI subjects. It also shows neuroprotective effects in animal models of Alzheimer's disease and stress.

Bifidobacterium infantis has been specifically shown to increase plasma tryptophan levels and influence central serotonin transmission, directly linking it to the gut-brain axis. It is classified as a key psychobiotic strain and has shown anti-inflammatory and mood-modulating effects in IBS and stress research.

Bifidobacterium lactis is widely studied for gut health and has documented effects on the gut-brain axis through SCFA production, gut barrier enhancement, and immune modulation. Clinical fMRI evidence shows fermented milk products containing B. lactis strains reduce emotional brain activation. It is a common component of multi-strain psychobiotic formulations.

Bifidobacterium longum, particularly strains 1714® and 35624®, has the strongest human clinical evidence among Bifidobacterium species for gut-brain axis effects. RCTs show strain 1714® reduces tension and improves memory in healthy volunteers, with measurable EEG and cortisol changes. It is the paradigmatic 'psychobiotic' strain.

Butyrate is a key mediator of gut-brain axis signaling, acting via vagal afferent pathways, enteroendocrine cells, BDNF upregulation, and neuroinflammation suppression. Tributyrin, as a colonic butyrate delivery vehicle, is now being specifically investigated in a human RCT for its effects on the microbiota-gut-brain axis in depression. The gut-brain connection is the mechanistic framework underpinning tributyrin's neurological research.

Butyric acid is a short-chain fatty acid (SCFA) produced by gut bacterial fermentation of dietary fiber and is a primary mediator of the gut-brain axis. It crosses the blood-brain barrier, influences neuroplasticity, and regulates neurotransmitter synthesis. Tributyrin, its prodrug, has been shown in a clinical study to deliver measurable gut-brain axis benefits for mental well-being.

Berberine from Coptis chinensis modulates the microbiota-gut-brain axis in animal models of IBS and visceral hypersensitivity, reducing spinal microglial activation and depressive-like behaviors via gut microbiota changes. TCM historically associated Coptis with emotional states connected to gut heat.

Curcumin, the principal bioactive of turmeric, has been specifically studied for its effects on the gut-brain axis. Research shows it attenuates gut inflammation, restores intestinal tight junction proteins, reduces neuroinflammation, and modulates gut microbiota composition. A dedicated study published in the Journal of Neurogastroenterology and Motility confirmed its therapeutic implications for the gut-brain axis.

DHA is a long-chain omega-3 PUFA with well-established gut-brain axis activity. It modulates gut microbiota composition by promoting Bifidobacterium and Lactobacillus populations, maintains gut and blood-brain barrier integrity, supports neurogenesis and synaptic plasticity, and reduces neuroinflammation. Clinical evidence links DHA deficiency to depression and cognitive impairment.

EPA is the most clinically active omega-3 fatty acid for depression and gut-brain axis modulation. Multiple meta-analyses of RCTs confirm small-to-moderate antidepressant effects of EPA-rich formulations. EPA promotes beneficial gut microbial populations, reduces gut and systemic inflammation, and regulates the HPA axis.

Fructooligosaccharides (FOS) are classified prebiotics that selectively feed beneficial gut bacteria—especially Bifidobacterium and Lactobacillus—to produce SCFAs and regulate serotonin metabolism. Animal studies show FOS alleviates anxiety and depression-like behaviors via the microbiome-gut-brain axis, and FOS is among the most studied prebiotics for neuropsychiatric modulation.

GABA is the brain's primary inhibitory neurotransmitter and is also synthesized in significant amounts by gut bacteria (notably Lactobacillus and Bifidobacterium species). Gut-derived GABA can signal to the brain via the enteric nervous system and vagal pathways, making it a direct molecular mediator of the gut-brain axis. Research links gut GABA production to anxiety, depression, and stress regulation.

Galacto-oligosaccharides (GOS) are prebiotics with clinical RCT evidence for gut-brain axis effects in humans. A controlled study showed GOS consumption reduced anxiety and increased beneficial gut microbial populations in healthy young females. GOS selectively feeds Bifidobacterium species, promotes SCFA and GABA production, and modulates neuroinflammatory pathways.

Preclinical evidence shows Ganoderma lucidum promotes sleep and modulates mood via a gut microbiota-serotonin axis, with GLAA extract increasing hypothalamic 5-HT levels through changes in gut bacteria and metabolites. This positions G. lucidum at the intersection of the gut-brain axis.

Glutamate is a recognized neurotransmitter/neuromodulator along the microbiota-gut-brain axis, expressed at glutamate transporters on intestinal epithelial cells and in enteric neurons. Gut bacteria produce glutamate, which can activate enteric and vagal afferent pathways signaling to the brain. Glutamate receptor signaling in the gut participates in visceral sensory transmission, intestinal motility, and stress-related secretory responses.

Inulin is a soluble prebiotic fiber with documented effects on the gut-brain axis. Studies show inulin increases SCFA-producing bacteria and serotonin (5-HT) metabolism, with animal research demonstrating alleviation of anxiety and depression-like behaviors via the microbiome-gut-brain axis. Clinical trials in schizophrenia patients show oligofructose-enriched inulin increases serum butyrate.

Kefir is a fermented dairy beverage containing diverse probiotic bacteria and yeasts, with established evidence for gut-brain axis modulation. It is specifically cited in authoritative scientific literature as a fermented food supporting the gut-brain connection through beneficial microbial delivery. Animal and human research links kefir consumption to reduced anxiety, improved memory, and gut microbiota diversification.

L-glutamine is the primary fuel source for intestinal enterocytes and maintains gut tight junctions, making it a structural support molecule for the gut-brain axis. It is a direct precursor to both glutamate (the primary excitatory neurotransmitter) and GABA (the primary inhibitory neurotransmitter), and can cross the blood-brain barrier. A randomized controlled trial showed L-glutamine reduced intestinal permeability in post-infectious IBS, a condition strongly linked to the gut-brain axis.

L-theanine, the primary amino acid in tea leaves, modulates the gut-brain axis by reshaping gut microbiota composition, restoring SCFA production, and down-regulating gut-brain inflammatory pathways. A 2025 study in npj Science of Food showed l-theanine reversed CUMS-induced depressive-like behavior via the gut-short-chain fatty acids-brain axis, with restored 5-HT, dopamine, and GABA levels.

L-tryptophan is the dietary precursor to serotonin and is directly regulated by the gut microbiota through both the serotonin and kynurenine pathways. It is a central node in the microbiota-gut-brain axis, with gut bacteria controlling tryptophan availability for brain serotonin synthesis. Depletion studies confirm low tryptophan impairs mood and memory, linking gut tryptophan metabolism to neuropsychiatric health.

Lactobacillus genus bacteria are core psychobiotic microorganisms with extensive evidence for gut-brain axis effects. Multiple strains produce GABA, influence serotonin synthesis, reduce cortisol, and modulate brain GABA receptor expression via vagal nerve signaling. Systematic reviews confirm Lactobacillus strains exhibit anxiolytic and antidepressant effects in both animal and human studies.

Lactobacillus acidophilus is a widely studied probiotic with documented gut-brain axis effects including improved cognitive performance in Alzheimer's disease patients when combined with other strains. It supports gut barrier integrity, produces serotonin-relevant metabolites, and is among the most common strains in psychobiotic research formulations.

Lactobacillus brevis is recognized as one of the primary GABA-producing bacteria in the human gut microbiome, directly relevant to the gut-brain axis. GABA synthesized by L. brevis via glutamate decarboxylase can signal through the enteric nervous system to the brain. Its GABA production capacity is physiological-state-dependent and has been characterized in peer-reviewed microbiology studies.

Lactobacillus casei has been studied in probiotic formulations demonstrating cognitive improvement in Alzheimer's disease patients. It is a component of multi-strain psychobiotic formulations and contributes to gut-brain axis modulation through SCFA production, gut barrier support, and immunomodulation relevant to neuropsychiatric conditions.

Lactobacillus fermentum has been studied in probiotic combinations for cognitive improvement in Alzheimer's disease patients and is classified among psychobiotic Lactobacillus strains. It contributes to gut-brain axis function through GABA production, gut barrier integrity, and reduction of neuroinflammatory markers.

L. gasseri CP2305 is one of the most studied probiotic strains for gut-brain axis modulation, with RCT evidence demonstrating improvements in stress, anxiety, sleep, and cortisol in humans. The strain acts via endocrine (HPA axis suppression), neural (vagus nerve activation), and immune (cytokine modulation) pathways.

Lactobacillus helveticus, particularly strain R0052, has RCT evidence in humans for gut-brain axis effects including reduced anxiety and depression when combined with Bifidobacterium longum. An fMRI study showed that a combination including L. helveticus R0052 reduced activation in key emotional regulation brain areas. It is one of the best-characterized psychobiotic strains.

Lactobacillus paracasei is a gut-brain axis probiotic with evidence for stress reduction and HPA axis modulation. It contributes to the gut microbiome's capacity to regulate mood-related neurotransmitters and has been included in multi-strain psychobiotic formulations studied for anxiety and cognitive outcomes.

Lactobacillus plantarum (now Lactiplantibacillus plantarum) has direct clinical evidence for gut-brain axis effects from an fMRI study showing reduced emotional brain activation after multi-strain probiotic consumption including this strain. It is a GABA producer and has been studied for anxiety reduction and cognitive modulation in both animal and human research.

Lactobacillus reuteri is a uniquely positioned gut-brain axis probiotic that produces the neurotransmitter precursor histamine from histidine in the gut and influences oxytocin release via vagal nerve signaling. Animal studies show L. reuteri reduces autism-like social deficits and anxiety via gut-brain axis oxytocin pathways. It is one of the few probiotics with mechanistic evidence for direct vagal neurotransmitter signaling.

Lactobacillus rhamnosus (particularly strain GG and JB-1) has some of the most mechanistically detailed gut-brain axis evidence. Animal studies definitively established that L. rhamnosus JB-1 alters GABA receptor expression in the brain via the vagus nerve, with vagotomy abolishing all effects. Human RCTs show L. rhamnosus GG improves memory performance and shifts gut microbiota composition.

Lactobacillus salivarius is a gut and oral probiotic that has been included in psychobiotic formulations with documented gut-brain axis effects. It contributes to gut microbial balance, SCFA production, and systemic immune regulation relevant to neuroinflammation. It appears in peer-reviewed probiotic combinations studied for stress and mood modulation.

GABA-producing L. lactis strains have been shown to modulate the gut-brain axis by upregulating GABA receptor expression in both the gut and brain in IBS mouse models, reducing visceral hypersensitivity and neurobehavioral abnormalities. Separately, engineered L. lactis has been used in optogenetic micro-nano systems to precisely regulate brain functions via vagal afferent signaling from the small intestine.

Lion's Mane modulates the gut-brain axis through its prebiotic polysaccharides, SCFA production, and NGF/BDNF stimulation. Animal studies show parallel improvements in gut microbiota and hippocampal neuroinflammation. A 2026 double-blind RCT noted improved subjective sleep and mood, with emerging data on gut-microbiome mediation.

Magnesium is an essential mineral involved in over 300 biochemical reactions and has documented gut-brain axis relevance. It modulates the HPA axis, supports GABA receptor function, reduces neuroinflammation, and influences gut microbiota composition. Magnesium deficiency is associated with anxiety and depression; supplementation in magnesium-deficient individuals improves mood and stress resilience.

Omega-3 fatty acids (EPA and DHA) are among the most studied nutrients for the gut-brain axis. They modulate gut microbiota composition, promote anti-inflammatory microbial populations, maintain intestinal and blood-brain barrier integrity, regulate HPA axis cortisol responses, and support neurogenesis. International nutritional psychiatry guidelines recommend omega-3s for depression.

Propionate is a key SCFA mediator of the gut-brain axis, crossing the blood-brain barrier to directly influence central nervous system function. It modulates neuroinflammation, hypothalamic appetite circuits, and neuropeptide expression. Human and animal evidence links gut-derived propionate to brain activity in food reward regions, neuroinflammatory states, and behavioral outputs including feeding and mood.

Reishi's prebiotic polysaccharides alter gut microbiome composition (Firmicutes:Bacteroidetes ratio), which intersects with the gut-brain axis via immune and vagal signalling. Animal research shows gut microbiome changes from reishi mediate improved sleep quality through altered tryptophan and serotonin metabolism. Human data are indirect — primarily microbiome mechanistic studies and sleep/stress RCTs.

Saccharomyces boulardii is a non-pathogenic yeast classified as a probiotic and is identified in peer-reviewed literature as a main probiotic member relevant to gut-brain axis modulation. It supports gut barrier function, reduces gut-derived neuroinflammation, and is among the most studied yeast probiotics for GI and systemic health with neurological implications.

Saffron (Crocus sativus) has clinical RCT evidence for antidepressant effects comparable to fluoxetine, with proposed mechanisms including serotonin pathway modulation and gut-brain axis engagement. A double-blind, placebo-controlled pilot RCT specifically investigated saffron's effects on the gut-sleep-brain axis, finding improvements in sleep quality alongside gut microbiota changes.

Streptococcus thermophilus is a dairy probiotic bacterium that has been included in clinical gut-brain axis studies, including a landmark fMRI trial where a fermented milk product containing this strain reduced emotional brain activation. It is identified in the scientific literature as a serotonin precursor producer in the gut microbiome.

Tributyrin exerts effects along the gut-brain axis by preserving butyrate-producing bacteria, reducing neuroinflammation, and influencing hippocampal function. Animal studies demonstrate that oral tributyrin prevents cognitive and memory deficits in Alzheimer's disease models by protecting histone acetylation status in hippocampal neurons. A hepatoportal butyrate-sensing mechanism also links intestinal tributyrin metabolism to central sleep and neurological regulation.

Turmeric (Curcuma longa), through its bioactive curcumin, has direct peer-reviewed evidence for gut-brain axis modulation including restoration of gut tight junctions, reduction of gut and brain neuroinflammation, modulation of gut microbiota, and vagus nerve-mediated anti-inflammatory effects. A dedicated review in the Journal of Neurogastroenterology and Motility confirms its therapeutic implications for the gut-brain axis.

UA sits at the intersection of gut microbial metabolism and CNS health. It is produced by gut bacteria, crosses the blood-brain barrier, and its pleiotropic activities—including anti-inflammatory and mitophagy-inducing effects—are mechanistically relevant to the gut-brain axis. Preclinical data link gut-derived UA to neuroprotective outcomes via the gut-brain axis.

Kanna's traditional use for abdominal pain combined with its activation of gut-relevant receptors (CCK, opioid) and serotonin modulation (the gut contains ~95% of the body's serotonin) provides a plausible but unstudied gut-brain mechanism. The traditional use for abdominal conditions reflects awareness of gut-related effects predating current gut-brain science.

Skullcap operates at the gut-brain interface through two complementary mechanisms: baicalin is converted to baicalein by gut bacteria (bidirectional gut-brain interaction), and it modulates both gut microbiota composition and central GABAergic/serotonergic signaling. TCM uses S. baicalensis for conditions involving both gastrointestinal and neurological symptoms.